

# IP8: IS INTERNATIONAL REFERENCE PRICING AND HTA DRIVEN REIMBURSEMENT COMPATIBLE?

## PAYER/HTA PERSPECTIVE

Jasmine R. F. Pwu, PhD

Director, TWNHCP Office, MOHW, Taiwan

# About Taiwan



## ■ Population

- *23.6 million (2020)*
- *Aged society (ageing index: 127.8 (2020))*
- *Expected life years at birth: 81 years*  
*78 years for men and 84 years for women in 2020*

## ■ 2019 GDP per capita (nominal) - US\$ 25,941

- *55,244 USD (Purchasing Power Parity; IMF Apr 2019)*


## ■ 2020 Current Health Expenditure as 6.2% of Gross Domestic Product

# National Health Insurance


- Introduced 1995
- Mandatory, single-payer social health insurance
- Comprehensive
- Low premium & low co-payment



# NHI Structure



# New Drug Application Process



# What Decisions?

- Listing or not



- Reimbursement price



- Reimbursement criteria/restrictions



# Pricing: based on the categories for New Drugs

Category	Definition	Pricing Rules
1	Shown <b>substantial</b> improvement in effectiveness, comparing to the best currently-used drug (therapy)	<ul style="list-style-type: none"><li>• international <b>median</b> price of the <b>A10</b> reference countries</li><li>• Plus 10% mark-up if there is locally conducted clinical trials (N large enough)</li></ul>

# Pricing: based on the categories for New Drugs

Category	Definition	Pricing Rules
2A	Shown <b>moderate</b> improvement	<ul style="list-style-type: none"><li>• capped at the <b>median price</b> of the <b>A10</b> reference countries</li><li>• follow one of the following pricing schemes based on their clinical merits:<ol style="list-style-type: none"><li>1. the <b>lowest price</b> in <b>A10</b> countries,</li><li>2. <b>international drug price ratio</b> (the ratio between new drug and reference drug in the 10 countries),</li><li>3. treatment-course dosage ratio (the ratio of dosage per treatment course between new drug and reference drug),</li><li>4. price in <b>original</b> country.</li></ol></li></ul>
2B	Shown <b>similar</b> clinical values	



# Pricing: based on the categories for New Drugs

Category	Definition	Pricing Rules
2A	Shown <b>moderate</b> improvement	5. For a combination drug, price is at 70% of the sum of each ingredient's price (single × 70%) or is priced on the basis of the price of a single active ingredient.
2B	Shown <b>similar</b> clinical values	<ul style="list-style-type: none"><li>• Additional markup if<ol style="list-style-type: none"><li>1. there is locally conducted clinical trials (not too small sample size) - up to 10%</li><li>2. Local pharmacoeconomic up to 10%</li></ol></li></ul>

Either the price set by the rules or the company's proposed price, whichever is **lower**.

# A10 countries

- United States
- United Kingdom
- Canada
- France
- Belgium
- Germany
- Japan
- Sweden
- Australia
- Switzerland

國際藥價參考國查詢網站表

國別	網站名	查詢參考網站
美國	Micromedex 之 Red Book Online	<a href="http://www.micromedexsolutions.com/">http://www.micromedexsolutions.com/</a>
日本	厚生労働省保険局使用薬剤の薬価 (薬価基準)	下載各藥品檔案查詢，網址： <a href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000078916.html">https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000078916.html</a>
英國	NHS Prescription Service	<a href="https://applications.nhsbsa.nhs.uk/DMDBrowser/DMDBrowser.do">https://applications.nhsbsa.nhs.uk/DMDBrowser/DMDBrowser.do</a>
加拿大	Government of Saskatchewan	<a href="https://formulary.drugplan.ehealthsask.ca/SearchFormulary">https://formulary.drugplan.ehealthsask.ca/SearchFormulary</a>
德國	ROTE LISTE®	<a href="https://online.rote-liste.de/">https://online.rote-liste.de/</a>
法國	Base des Médicaments et Informations Tarifaires	<a href="http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI">http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI</a>
比利時	Centre Belge d'Information Pharmaco-thérapeutique (CBIP)	<a href="http://www.cbip.be/">http://www.cbip.be/</a>
瑞典	Farmaceutiska specialiteter i Sverige (FASS)	<a href="http://www.fass.se/LIF/home/index.jsp">http://www.fass.se/LIF/home/index.jsp</a>
瑞士	Arzneimittel kompendium der schweiz	<a href="http://compendium.ch">http://compendium.ch</a>
澳洲	Pharmaceutical Benefits Scheme (PBS)	1.至官方網站下載藥品給付檔，路徑為：官方網站首頁 ( <a href="http://www.pbs.gov.au/pbs/home">http://www.pbs.gov.au/pbs/home</a> ) > Publications & Downloads > Downloads > 下載檔名為 PBS Text files 之壓縮檔> 壓縮檔內檔名為 drug 之 txt 檔。 2. 檔案欄位名稱參考： <a href="https://dev.pbs.gov.au/content/software/current/doc/drug.html">https://dev.pbs.gov.au/content/software/current/doc/drug.html</a> 3. 藥價為參考欄位名稱為「Commonwealth Price to Pharmacist」之價格。

# Why these 10 countries?

- Since the beginning of NHI – use regulatory A10 countries ever since
- Difficult to change
  - *South Korea? China? India? Similar-GDP countries?*

# Our learnings

- IRP is a relatively easy way of pricing decision
  - *Not just new drug pricing; also for price review*
  - *Other pricing rules exist, IRP is not most used or preferred*
- Pros
  - *Confidence*
  - *easy to implement*
- Cons
  - *Later access*
  - *Debates of reference countries*

# Questions? Comments?

Please feel free to contact: [jasminepwu@gmail.com](mailto:jasminepwu@gmail.com)